IMBLAZE370

NCT02788279 📎

Regimen

Experimental
Atezolizumab + cobimetinib (MEK inhibitor)
Control
Atezolizumab monotherapy; regorafenib as third control arm

Population

MSS/pMMR metastatic CRC, 3L+, chemotherapy-refractory; unselected by biomarker.

Key finding

3L+ MSS mCRC: mOS atezo+cobi 8.87 vs regorafenib 8.51 mo (HR 1.00, 95% CI 0.73-1.38, p=0.99) — no benefit; atezo monotherapy vs regorafenib: mOS 7.10 vs 8.51 mo (HR 1.19, 95% CI 0.83-1.71, p=0.34); ORR atezo+cobi 3% vs regorafenib 2%; primary endpoint not met

Source: PMID 31003911

Timeline

    Guideline citations

    • NCCN Colon (p.223)